Cosmecca Korea (241710) 2026 Q1 Earnings Deep Dive — Korea Subsidiary-Led Growth, ODM Structure Transition
The structural link between the global expansion of K-beauty indie brands and ODM order intake is reshaping Cosmecca Korea's growth equation. In 2026 Q1 on a consolidated basis, revenue reached KRW 185.1bn (YoY +56.4%) and operating profit KRW 21.9bn (YoY +78.0%), modestly exceeding market consensus. The three-entity structure spanning Korea, the U.S., and China, together with automation capex, forms the core axis of earnings leverage.
1. Industry Growth Vision — Structural Shift and Direction
The K-beauty ODM sector has entered a phase of structural growth driven by the proliferation of indie brand direct-to-consumer channels (TikTok Shop, Amazon) overseas. The average PER for Korea's cosmetics sector stands at 20.0x with a Forward PER of 18.7x, reflecting the market's growth premium ascribed to K-beauty ODM. ODM manufacturers are expanding production capacity through automation capex while simultaneously improving their margin structure, and geographic diversification into new markets such as North America and ASEAN is expanding the sector's TAM. As customer portfolios shift from a handful of mega-brands to a diversified multi-indie-brand structure, the earnings stability of ODM players is also improving.
📌 K-Beauty ODM sector Forward PER 18.7x — indie brand direct overseas sales channel driving order TAM expansion
2. Corporate Strategic Position
Cosmecca Korea operates a three-hub structure comprising the Korea subsidiary, U.S. Englewood Lab (ELW·ELWK), and the China subsidiary. In 1Q26, the Korea subsidiary posted revenue of KRW 142.2bn (YoY +91.3%), with expanding orders for indie brand hit SKUs (Fil-Shot, Multi-Balm, Body Fil-Shot) driving consolidated growth. A tender offer completed in April 2026 raised Englewood Lab's ownership stake from 50.1% to 66.7%*2, increasing the proportion of U.S. subsidiary earnings attributable to controlling shareholders. An OPM of 13.0%, combined with ROE of 17.2%, illustrates the distinctive earnings structure of ODM manufacturing. Financial stability is maintained with a debt-to-equity ratio of 87.9%, though automation-related capex is acting as a near-term constraint on OPM.
| Category | Details |
|---|---|
| Competitive Advantage | Three-entity ODM network with automated production systems; simultaneous orders across multiple indie brand hit SKUs |
| Market Position | ODM hubs in Korea, the U.S. (OTC suncare & skincare specialist), and China |
| Strategic Weakness | Ongoing China subsidiary operating losses (1Q26 revenue KRW 6.4bn, YoY -27.1%); revenue concentration among a small number of clients |
3. Key Growth Drivers
Growth is driven by three pillars. First, the Korea subsidiary's expansion of indie brand clients. The 1Q26 Korea subsidiary revenue of KRW 142.2bn reflects a combined effect of orders for Company D's Fil-Shot, Multi-Balm, and Body Fil-Shot SKUs — strong performers on TikTok Shop and Amazon — alongside new client wins including mist serums. Second, earnings leverage from Englewood Lab: ELWK OPM reached 33.8% in 4Q25 (YoY +10.7%p)1, with volume ramp-up from a large-order client expected to be fully reflected from Q23. Third, Korea subsidiary automation line ramp-up: from 2H 2026, automation equipment is set to become fully operational, marking the period when OPM improvement becomes numerically visible*3.
4. Financial & Valuation Summary
At the current price of KRW 91,200, Trailing PER of 20.1x is effectively in line with the sector average of 20.0x, while Forward PER of 13.0x represents a 30.5% discount to the sector average of 18.7x. ROE stands at 17.2%, debt-to-equity at 87.9%, and OPM at 13.0%. The sector-relative discount embedded in Forward PER is contingent on 2026 EPS growth being realized*1.
📌 Forward PER 13.0x at a 30.5% discount to the sector average of 18.7x — 2026F EPS delivery is the key prerequisite
| Metric | Current | Sector Avg. | Interpretation |
|---|---|---|---|
| Trailing PER | 20.1x | 20.0x | Effectively in line with sector average |
| Forward PER | 13.0x | 18.7x | 30.5% discount to sector — contingent on EPS growth |
| PBR | 3.61x | — | Reflects ROE 17.2% capital efficiency |
| ROE | 17.2% | — | Linked to OPM of 13.0% |
| Debt-to-Equity | 87.9% | — | Financial stability maintained |
5. Risks & Monitoring Points
Key risks include order volatility from revenue concentration among a small number of indie brand clients, ongoing operating losses at the China subsidiary, exposure to OTC export cost fluctuations from changes in U.S. tariff policy, and potential delays to the OPM improvement timeline if Korea subsidiary automation lines are slow to ramp up.
- ⚠️ Revenue concentration among a small number of indie brands including Company D — order reduction would amplify quarterly earnings volatility
- ⚠️ Ongoing China subsidiary operating losses (1Q26 revenue KRW 6.4bn, YoY -27.1%)
- ⚠️ Impact of U.S. tariff policy changes on OTC suncare and skincare export costs
- ⚠️ Delay in Korea subsidiary automation ramp-up would push back the 2H 2026 OPM improvement timeline*3
- 📌 Quarterly Korea subsidiary order volume from indie brand Company D and new SKU additions
- 📌 Quarterly Englewood Lab (ELWK) OPM trend — whether the 4Q25 baseline of 33.8%1 is sustained
- 📌 2026F EPS delivery — Kyobo Securities estimate of KRW 6,6581 as the basis for Forward PER 13.0x recalibration
- 📌 China subsidiary quarterly P&L — timing of 2H 2026 BEP target*3 achievement
6. Changes Since Previous Analysis
This is the inaugural analysis; no prior report exists. The report was written following the preliminary 1Q26 earnings disclosure (2026-05-08). Consolidated 1Q26 results — revenue KRW 185.1bn (YoY +56.4%), operating profit KRW 21.9bn (YoY +78.0%) — modestly exceeded market consensus, confirming Korea subsidiary-led growth.
Cosmecca Korea is positioned to capture structural ODM growth through diversification of K-beauty indie brand orders and entity-level automation investments. Whether the EPS growth implied by Forward PER 13.0x materializes — and when the Korea subsidiary's automation lines come online — are the key variables that will determine the earnings trajectory.
📎 출처 및 추정 근거
- 1 Based on Kyobo Securities report dated 2026-04-09 (Cosmecca Korea 1Q26 Preview, Kwon Woo-jeong) — 2026F EPS KRW 6,658, 4Q25 ELWK OPM 33.8% (YoY +10.7%p)
- 2 Based on Kyobo Securities report dated 2026-04-09 — Englewood Lab tender offer completed, ownership stake raised from 50.1% to 66.7%
- *3 Based on Kyobo Securities report dated 2026-02-23 (Cosmecca Korea 4Q25 Review, Kwon Woo-jeong) — Korea subsidiary automation expected to improve profitability in 2H 2026; China subsidiary targeting BEP in 2026
본 보고서는 정보 제공 목적이며 투자 권유가 아닙니다. 투자 결정은 본인 책임입니다.
댓글 없음:
댓글 쓰기